SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics Monthly Activity About

SEC Comment Letter for Valneva SE (VALN) (CIK 0001836564) (VALN) — Jun 11, 2026

Valneva SE (VALN) (CIK 0001836564)
Date: June 11, 2026 · CIK: 0001836564 · Accession: 0000000000-26-005889

Regulatory Compliance Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-296504

Date
June 11, 2026
Author
Thomas Lingelbach
Form
UPLOAD
Company
Valneva SE (VALN) (CIK 0001836564)

Letter

June 11, 2026 Thomas Lingelbach Chief Executive Officer Valneva SE Îlot Saint Joseph Bureaux Convergence 12T Quai Perrache 69002 Lyon France Re: Valneva SE Registration Statement on Form F-3 Filed June 4, 2026 File No. 333-296504 Dear Thomas Lingelbach: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Courtney Thorne, Esq.

Show Raw Text
June 11, 2026
Thomas Lingelbach
Chief Executive Officer
Valneva SE
Îlot Saint Joseph Bureaux Convergence
12T Quai Perrache
69002 Lyon France
Re: Valneva SE
Registration Statement on Form F-3
Filed June 4, 2026
File No. 333-296504
Dear Thomas Lingelbach:
 This is to advise you that we have not reviewed and will not review your registration
statement.
 Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
 Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Courtney Thorne, Esq.